

#6

PFO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/009,447
				Filing Date	11/13/01
				First Named Inventor	M. South et al.
Sheet	1	of	4	Attorney Docket No.	3203/1A/US(PHA 4159.26)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
VB	1	5,441,960	B1	Bernstein et al.	08-15-1995
VB	2	5,656,645	B1	Tamura et al.	08-12-1997
VB	3	5,658,930	B1	Tamura et al.	08-19-1997
VB	4	5,668,289	B1	Sanderson et al.	09-16-1997
VB	5	5,792,779	B1	Sanderson et al.	08-11-1998
VB	6	5,861,380	B1	Gyorkos et al.	01-19-1999
VB	7	5,866,573	B1	Sanderson et al.	02-02-1999
VB	8	5,869,487	B1	Coburn et al.	02-09-1999
VB	9	5,872,138	B1	Naylor-Olsen et al.	02-16-1999
VB	10	6,011,158	B1	Tamura et al.	01-04-2000
VB	11	6,037,356	B1	Lu et al.	03-14-2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
--------------------	-----------------------	-------------------------	---	---	----------------

Examiner Signature	V. Balasubramanian	Date Considered	8/28/03
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/009,447
				Filing Date	11/13/01
				First Named Inventor	M. South et al.
Sheet	2	of	4	Attorney Docket No.	3203/1A/US(PHA 4159.26)

		Office	Number ⁴	Kind Code ² (if known)			
VB	12	EP	528 633	B1	Zeneca Limited	02-24-1993	
IM	13	EP	826 671	A1	The Green Cross Corporation	03-04-1998	
M	14	EP	936 216	A1	Nippon Kayaku Kabushiki Kaisha	08-18-1999	
VB	15	EP	940 400	A1	Yoshitomi Pharmaceutical Industries, Ltd.	09-08-1999	
VB	16	EP	997 474	A1	Pfizer Inc	05-03-2000	
VB	17	WO	93/21214	A1	Zeneca Limited	10-28-1993	
M	18	WO	96/18644	A1	Corvas International Inc.	06-20-1996	
VB	19	WO	96/33974	A1	The Green Cross Corporation (abstract)	10-31-1996	
M	20	WO	96/39380	A1	3-Dimensional Pharmaceuticals, Inc.	12-12-1996	
H	21	WO	96/40100	A1	3-Dimensional Pharmaceuticals, Inc.	12-19-1996	
VB	22	WO	97/01338	A1	Merck & Co., Inc.	01-16-1997	
M	23	WO	97/30708	A1	Merck & Co., Inc.	08-28-1997	
VB	24	WO	97/40024	A1	Merck & Co., Inc.	10-30-1997	
M	25	WO	97/46207	A2	Corvas International Inc.	12-11-1997	
B	26	WO	98/08840	A1	Merck & Co., Inc.	03-05-1998	
M	27	WO	98/09949	A1	Nippon Kayaku Kabushiki Kaisha (abstract)	03-12-1998	
VB	28	WO	98/10763	A1	Merck & Co., Inc.	03-19-1998	

Examiner Signature	V. Belasubramanian	Date Considered	8/28/03
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PFO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/009,447
				Filing Date	11/13/01
				First Named Inventor	M. South et al.
Sheet	3	of	4	Attorney Docket No.	3203/1A/US(PHA 4159.26)


M	29	WO	98/16525	A1	Cor Therapeutics, Inc.	04-23-1998	
M	30	WO	98/16547	A1	Cor Therapeutics, Inc.	04-23-1998	
M	31	WO	98/17274	A1	Merck & Co., Inc.	04-30-1998	
M	32	WO	98/31670	A1	Merck & Co., Inc.	07-23-1998	
VB	33	WO	98/42342	A1	Merck & Co., Inc.	10-01-1998	
M	34	WO	98/47876	A1	Akzo Nobel N.V.	10-29-1998	
VB	35	WO	98/50420	A1	Akzo Nobel N.V.	11-12-1998	
VB	36	WO	99/00121	A1	Eli Lilly and Company	01-07-1999	
M	37	WO	99/00126	A1	Eli Lilly and Company	01-07-1999	
M	38	WO	99/00128	A1	Eli Lilly and Company	01-07-1999	
VB	39	WO	99/11267	A1	Merck & Co., Inc.	03-11-1999	
VB	40	WO	99/26920	A1	Corvas Interantional, Inc.	06-03-1999	
M	41	WO	99/26926	A1	3-Dimensional Pharmaceuticals, Inc.	06-03-1999	
M	42	WO	99/36426	A1	Warner-Lambert Company	07-22-1999	
VB	43	WO	99/59591	A1	Merck & Co., Inc.	11-25-1999	
M	44	WO	99/61442	A1	Merck & Co., Inc.	12-02-1999	
M	45	WO	99/62538	A1	Cortech Inc.	12-09-1999	
M	46	WO	99/64446	A1	3-Dimensional Pharmaceuticals, Inc.	12-16-1999	
VB	47	WO	00/18762	A1	Merck & Co., Inc.	04-06-2000	
VB	48	WO	00/26210	A1	Merck & Co., Inc.	05-11-2000	
VB	49	WO	00/26211	A1	Merck & Co., Inc.	05-11-2000	

Examiner Signature	V. Balasubramanian	Date Considered	8/28/03
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/009,447
				Filing Date	11/13/01
				First Named Inventor	M. South et al.
Sheet	4	of	4	Attorney Docket No.	3203/1A/US(PHA 4159.26)

VS	50	WO	00/32574	A1	Sanofi-Synthelabo (abstract)	06-08-2000	
VS	51	WO	00/39102	A1	Du Pont Pharmaceuticals Company	07-06-2000	
VS	52	WO	00/69826	A1	Monsanto Company	11-23-2000	
VS	53	WO	00/69832	A1	Monsanto Company	11-23-2000	
VS	54	WO	00/69833	A1	Monsanto Company	11-23-2000	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
M	55	MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.	
M	56	HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York.	
M	57	SANDERSON et al., "L-373,890, An Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor." Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 12, pp. 1497-1500, 1997.	

Examiner Signature	V. Balasubramanian	Date Considered	8/28/03
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.